drugset / Trial / NCT02275299

Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis

NCT02275299

Phase 4 Unknown 240 enrolled Jiangsu Simcere Pharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This study is intended to evaluate the efficacy and safety of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in patients with active Rheumatoid Arthritis (RA).

Timeline

Start
2013-09
Primary completion
2016-02
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Iguratimod Small molecule 50 mg Oral
Comparator Leflunomide Small molecule 20 mg Oral
Background Methotrexate Small molecule 10 mg Oral

Indications